Suchergebnisse - (Subject:"PARP inhibitor")

PubPharm (10)

1

Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents

enthalten in: Vaccines | 2022

von Zagouri, F. | Papatheodoridi, A. | Liontos, M. | +12

2

Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents

in: Vaccines | 2022

von Flora Zagouri | Alkistis Papatheodoridi | Michalis Liontos | +12

3

Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors

enthalten in: Vaccines | 2021

von Liontos, M. | Terpos, E. | Markellos, C. | +13

4

Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis

enthalten in: Current drug targets | 2021

von Rajawat, J. | Chandra, A.

5

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis

in: Frontiers in Oncology | 2021

von Hongmei Wang | Meng Wu | Haonan Liu | +8

6

Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors

in: Vaccines | 2021

von Michalis Liontos | Evangelos Terpos | Christos Markellos | +13

7

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer : A Network Meta-Analysis

enthalten in: Frontiers in oncology | 2021

von Wang, H. | Wu, M. | Liu, H. | +8

8

PARP-inhibitors in a non-oncological indication as COVID-19 : Are we aware about its potential role as anti-thrombotic drugs? The discussion is open

enthalten in: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2020

von Capoluongo, E.

9

PARP-inhibitors in a non‐oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open

in: Biomedicine & Pharmacotherapy | 2020

von Ettore Capoluongo

10

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer

enthalten in: Gynecologic oncology | 2019

von Hurley, R. | Wahner Hendrickson, A. | Visscher, D. | +19

1
[1]